1. Search Result
Search Result
Results for "

CS

" in MedChemExpress (MCE) Product Catalog:

81

Inhibitors & Agonists

1

Fluorescent Dye

3

Biochemical Assay Reagents

9

Peptides

2

Inhibitory Antibodies

3

Natural
Products

12

Recombinant Proteins

7

Isotope-Labeled Compounds

7

Antibodies

3

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P6306

    Apolipoprotein Neurological Disease
    CS-6253 is an agonist for ATP-binding cassette 1 (ABCA 1). CS-6253 improves the amyloid-β42/40 ratio, and affects lipoprotein metabolism in plasma. CS-6253 generates cholesterol-rich high-density lipoprotein (HDL) particles, and induces the release of microparticles .
    CS-6253
  • HY-100401A

    CS-505

    Acyltransferase Cardiovascular Disease
    Pactimibe sulfate (CS-505) is a dual ACAT1/2 inhibitor with IC50s of 4.9 μM and 3.0 μM, respectively. Pactimibe sulfate (CS-505) inhibits ACAT with IC50s of 2.0 μM, 2.7 μM, 4.7 μM in the liver, macrophages and THP-1 cells, respectively . Pactimibe sulfate (CS-505) noncompetitively inhibits oleoyl-CoA with a Ki value of 5.6 μM. Moreover, Pactimibe sulfate (CS-505) obviously inhibits cholesteryl ester formation with an IC50 of 6.7 μM. Pactimibe sulfate (CS-505) possesses anti-atherosclerotic potential with lowering plasma cholesterol activity .
    Pactimibe sulfate
  • HY-108493

    LPL Receptor Inflammation/Immunology
    CS-2100 (Compound 10b) is a potent, selective, orally active and S1P3-sparing S1P1 agonist with an EC50 of 4.0 nM for human S1P1. CS-2100 shows in vivo immunosuppressive efficacy in rats with an ID50 (infective dose) of 0.407 mg/kg for HvGR .
    CS-2100
  • HY-100413

    Proton Pump Inflammation/Immunology
    CS-526 is a potent, selective, reversible and orally active acid pump antagonist. CS-526 inhibits H +,K +-ATPase activity. CS-526 inhibits gastric acid secretion and prevents esophageal lesions. CS-526 has the potential for the research of gastroesophageal reflux disease .
    CS-526
  • HY-P6306A

    Apolipoprotein Neurological Disease
    CS-6253 TFA is the TFA salt form of CS-6253 (HY-P6306). CS-6253 TFA is an agonist for ATP-binding cassette 1 (ABCA 1). CS-6253 TFA improves the amyloid-β42/40 ratio, and affects lipoprotein metabolism in plasma. CS-6253 TFA generates cholesterol-rich high-density lipoprotein (HDL) particles, and induces the release of microparticles .
    CS-6253 TFA
  • HY-19633A

    Others Neurological Disease
    CS-003 is a triple neurokinin receptor antagonist with activity in inhibiting neurokinin-related respiratory diseases. CS-003 exhibits high affinity for human neurokinin 1, 2 and 3 receptors, withKi values of 2.3 nM, 0.54 nM and 0.74 nM respectively. The Ki values of CS-003 on the guinea pig neurokinin receptor are 5.2 nM, 0.47 nM and 0.71 nM respectively, showing superior inhibitory effect. CS-003 significantly inhibits the formation of inositol phosphate involving substance P, neurokinin A and neurokinin B through competitive antagonism. CS-003 significantly inhibits citric acid-induced cough, and its effect is better than other selective neurokinin receptor antagonists .
    CS-003
  • HY-19633

    Neurokinin Receptor Infection Endocrinology
    CS-003 Free base (CS-003), a triple tachykinin receptor antagonist, shows high affinities for human (Neurokinin) NK1, NK2 and NK3 receptors with Ki values of 2.3 nM, 0.54 nM and 0.74 nM, respectively. CS-003 Free base (CS-003) has therapeutic efficacy on respiratory diseases associated with neurokinins.
    CS-003 Free base
  • HY-106888A

    Endogenous Metabolite Neurological Disease
    CS-722 is a centrally acting muscle relaxant, and has a muscle relaxant activity and depressant effectson the spinal reflex[1]. CS-722 inhibits spontaneous inhibitory postsynaptic currents and excitatory postsynaptic currents in hippocampal cultures probably by an inhibition of both sodium and calcium currents .
    CS-722
  • HY-160929

    CS-0159

    FXR Metabolic Disease
    Linafexor (CS-0159) is an agonist for farnesoid X receptor (FXR) .
    Linafexor
  • HY-163752

    MAP3K Metabolic Disease
    CS17919 is a potent, selective and orally active ASK1 inhibitor with an IC50 of 22.52 nM. CS17919 shows anti-inflammatory and antifibrotic effects. CS17919 can be used for the study of metabolic-related kidney and liver diseases .
    CS17919
  • HY-B0165A
    Pravastatin sodium
    5 Publications Verification

    CS-514 sodium

    HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis Cardiovascular Disease Cancer
    Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.
    Pravastatin sodium
  • HY-148913

    CaMK Neurological Disease
    CS587 is a specific inhibitor of CaMK1D with neurocytotoxicity at 10 μM. CS587 modulates the sensitivity of neuronal cells to Aβ oligomer toxicity .
    CS587
  • HY-100401

    CS-505 free base

    Acyltransferase Cardiovascular Disease
    Pactimibe (CS-505 free base) is a dual ACAT1/2 inhibitor with IC50s of 4.9 μM and 3.0 μM, respectively. Pactimibe (CS-505 free base) inhibits ACAT with IC50s of 2.0 μM, 2.7 μM, 4.7 μM in the liver, macrophages and THP-1 cells, respectively . Pactimibe (CS-505 free base) noncompetitively inhibits oleoyl-CoA with a Ki value of 5.6 μM. Moreover, Pactimibe (CS-505 free base) obviously inhibits cholesteryl ester formation with an IC50 of 6.7 μM. Pactimibe (CS-505 free base) possesses anti-atherosclerotic potential with lowering plasma cholesterol activity .
    Pactimibe
  • HY-14977

    LPL Receptor Inflammation/Immunology
    CS-0777-P, the phosphorylated form of CS-0777, acts as a potent and selective modulator of the S1P receptor-1 (S1P1). It exhibits approximately 320-fold higher agonist activity for human S1P1 compared to S1P3, with an EC50 of 1.1 nM. In pharmacological studies, CS-0777-P demonstrated significant effects in vitro as an S1P1 and S1P3 agonist, leading to lowered peripheral blood lymphocyte counts and suppressive effects on experimental autoimmune encephalomyelitis (EAE) in rats. Pharmacokinetic studies in rats revealed rapid lymphocyte count reductions following oral administration, making CS-0777 a promising candidate currently undergoing clinical trials for the treatment of multiple sclerosis (MS) .
    CS-0777-P
  • HY-B0165

    CS-514

    Autophagy HMG-CoA Reductase (HMGCR) Cardiovascular Disease Cancer
    Pravastatin (CS-514) is a competitive HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM .
    Pravastatin
  • HY-137005

    Topoisomerase Apoptosis Cancer
    CS1 is a potent DNA Topo II α inhibitor. CS1 displays broad-spectrum in vitro antitumor effects, low toxicity in vivo and potential anti-multidrug resistance capabilities. CS1 leads to DNA damage, cell cycle arrest at G2/M phase and apoptosis .
    CS1
  • HY-145995

    Others Others
    CS12192 is a compound improving survival and weight gain. CS12192 has the potential for the research of graft-versus-host disease (GVHD) (extracted from the patent CN112773802A) .
    CS12192
  • HY-106888

    Endogenous Metabolite Neurological Disease
    CS-722 Free base is a synthesized centrally acting muscle relaxant, and has a muscle relaxant activity and depressant effectson the spinal reflex . CS-722 Free base inhibits spontaneous inhibitory postsynaptic currents and excitatory postsynaptic currents in hippocampal cultures probably by an inhibition of both sodium and calcium currents .
    CS-722 Free base
  • HY-100471
    Esaxerenone
    2 Publications Verification

    CS-3150; XL-550

    Mineralocorticoid Receptor Cardiovascular Disease
    Esaxerenone (CS-3150) is a highly potent and selective non-steroidal mineralocorticoid receptor antagonist .
    Esaxerenone
  • HY-106174

    CS 891

    5 alpha Reductase Cancer
    Lapisteride (CS 891) is an orally active 5α-reductase inhibitor. Lapisteride can be used in cancer research .
    Lapisteride
  • HY-U00211

    NSC302998

    Others Cardiovascular Disease
    CS476 is a potent hypoglycaemic agent.
    CS476
  • HY-116228

    Caderofloxacin; CS-940

    Bacterial Infection
    Cadrofloxacin (Caderofloxacin; CS-940), a orally active fluoroquinolone, is effective against aerobic/anaerobic Gram-positive and Gram-negative bacteria. Cadrofloxacin can be used for the research of infectious diseases .
    Cadrofloxacin
  • HY-148907

    CaMK MEK Mixed Lineage Kinase Cancer
    CS640 is a selective inhibitor of calmodulin-dependent kinases. CS640 inhibits CaMK1D, CaMK1B, CaMK1A, CaMK1G, PIP5K1C, MEK5, RIPK4 and MLK3 with IC50 values of 0.08, 0.03, 0.001, 0.001, 11.2, 0.025, 5.69 and 2.75 μM, respectively. CS640 also shows inhibitory effects to CYP450 2C9 and CYP450 2C19 with IC50 values of 6 and 10 μM, respectively .
    CS640
  • HY-19404

    CS-758; R-120758

    Fungal Infection
    Embeconazole (CS-758; R-120758) is an antifungal agent against Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus and Aspergillus flavus, with MICs of 8, 16, 63 and 250 μM, respectively .
    Embeconazole
  • HY-14818A

    CS-8958

    Influenza Virus Infection
    Laninamivir octanoate (CS-8958), a proagent of Laninamivir, is a long-acting neuraminidase (NA) inhibitor with anti-influenza virus activity. Laninamivir octanoate shows anti-influenza activity against Oseltamivir-resistant viruses, and also against the pandemic influenza viruses .
    Laninamivir octanoate
  • HY-14818C

    CS-8958 hydrate

    Influenza Virus Infection
    Laninamivir octanoate hydrate (CS-8958 hydrate), a prodrug of Laninamivir, is a long-acting neuraminidase (NA) inhibitor with anti-influenza virus activity. Laninamivir octanoate hydrate shows anti-influenza activity against Oseltamivir-resistant viruses, and also against the pandemic influenza viruses .
    Laninamivir octanoate hydrate
  • HY-RS03221

    Small Interfering RNA (siRNA) Others

    CS Human Pre-designed siRNA Set A contains three designed siRNAs for CS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CS Human Pre-designed siRNA Set A
    CS Human Pre-designed siRNA Set A
  • HY-B0165AR
    Pravastatin (sodium) (Standard)
    4 Publications Verification

    CS-514 (sodium) (Standard)

    HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis Cardiovascular Disease Cancer
    Pravastatin (sodium) (Standard) is the analytical standard of Pravastatin (sodium). This product is intended for research and analytical applications. Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.
    Pravastatin (sodium) (Standard)
  • HY-P99758

    CS1003

    PD-1/PD-L1 Cancer
    Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab can be used for unresectable hepatocellular carcinoma (uHCC) research .
    Nofazinlimab
  • HY-B0165S

    CS-514-d9 sodium

    Autophagy HMG-CoA Reductase (HMGCR) Isotope-Labeled Compounds Cardiovascular Disease Cancer
    Pravastatin-d9 sodium is deuterated labeled Pravastatin (HY-B0165). Pravastatin (CS-514) is a competitive HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM .
    Pravastatin-d9 sodium
  • HY-B1595

    CS 1170

    Antibiotic Bacterial Infection Cancer
    Cefmetazole (CS 1170) is a semisynthetic cephamycin antibiotic with broad-spectrum antibacterial activity, covering gram-positive, gram-negative and anaerobic bacteria. Cefmetazole binds to penicillin binding proteins (PBPs), resulting in interfering bacterial cell wall biosynthesis. Cefmetazole is used for the research of gynecologic, intraabdominal, urinary tract, respiratory tract and skin and soft tissue infections .
    Cefmetazole
  • HY-123022

    CS-023; RO4908463; R-115685

    Bacterial Infection
    Tomopenem (CS-023; RO4908463; R-115685) is a longer-half-life parenteral carbapenem. Tomopenem shows broad activity against 63 reference species. The activity of tomopenem against 293 clinical isolates is potent (MIC90, 0.06 to 4 μg/mL). Antianaerobic activity .
    Tomopenem
  • HY-B0023
    Azelnidipine
    2 Publications Verification

    CS 905

    Calcium Channel MEK Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Azelnidipine (CS 905) is a dihydropyridine calcium channel blocker that is effective orally. Azelnidipine inhibits the intracellular calcium ion flow and lower blood pressure by selectively blocking L-type calcium channel on the membrane of vascular smooth muscle. Azelnidipine inhibits esophageal squamous cell carcinoma proliferation by targeting MEK1/2. Azelnidipine also has anti-inflammatory, antioxidant and neuroprotective effects .
    Azelnidipine
  • HY-P99270

    CS-1008; Anti-Human TRAIL-R2 Recombinant Antibody

    Apoptosis Cancer
    Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
    Tigatuzumab
  • HY-105268

    CS-92

    HIV Reverse Transcriptase Nucleoside Antimetabolite/Analog Infection
    AzddMeC (CS-92) is an antiviral nucleoside analogue and a potent potent, selective and orally active HIV-1 reverse transcriptase and HIV-1 replication inhibitor. In HIV-1-infected human PBM cells and HIV-1-infected human macrophages, the EC50 values of AzddMeC are 9 nM and 6 nM, respectively . AzddMeC is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    AzddMeC
  • HY-14783

    CS 706; R 109339; TG 01

    COX Prostaglandin Receptor Neurological Disease Inflammation/Immunology Cancer
    Apricoxib (CS 706) is a selective inhibitor for cyclooxygenase-2 (COX-2). Apricoxib inhibits the production of PGE2 in cells with IC50 of 1.5 nM. Apricoxib exhibits anticancer, analgesic and anti-inflammatory activities .
    Apricoxib
  • HY-B0165AS

    CS-514-13C,d3 sodium

    Isotope-Labeled Compounds HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis Cardiovascular Disease Cancer
    Pravastatin- 13C,d3 (sodium) is the 13C- and deuterium labeled Pravastatin (sodium). Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.
    Pravastatin-13C,d3 sodium
  • HY-124526

    Ibcasertib; CS2164

    VEGFR PDGFR c-Kit Aurora Kinase c-Fms Cancer
    Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects .
    Chiauranib
  • HY-17005

    CS 866

    Angiotensin Receptor Cardiovascular Disease Endocrinology
    Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC50 of 66.2 μM.
    Olmesartan medoxomil
  • HY-109015
    Tucidinostat
    Maximum Cited Publications
    22 Publications Verification

    Chidamide; HBI-8000; CS 055

    HDAC Cancer
    Tucidinostat (Chidamide) is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, less active on HDAC8 and HDAC11 (IC50s, 733 nM, 432 nM, respectively), and shows no effect on HDAC4/5/6/7/9 .
    Tucidinostat
  • HY-17005R

    CS 866 (Standard)

    Angiotensin Receptor Cardiovascular Disease Endocrinology
    Olmesartan medoxomil (Standard) is the analytical standard of Olmesartan medoxomil. This product is intended for research and analytical applications. Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC50 of 66.2 μM.
    Olmesartan medoxomil (Standard)
  • HY-50935
    Troglitazone
    Maximum Cited Publications
    22 Publications Verification

    CS-045

    PPAR Autophagy Apoptosis Ferroptosis Metabolic Disease Cancer
    Troglitazone is an orally active PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively. Troglitazone has anticancer activity, prevents and inhibits the development of type 2 diabetes.
    Troglitazone
  • HY-106789

    CS-684

    Bacterial Infection Inflammation/Immunology Cancer
    Plaunotol is an orally active acyclic diterpene alcohol. Plaunotol has antibacterial activity against Helicobacter pylori which causes peptic ulcer . Plaunotol inhibits tumor angiogenesis and cell proliferation. Plaunotol induces apoptosis by activation of caspase 8 and caspase 9 pathways. Plaunotol is a potential anticancer agent against colon cancer .
    Plaunotol
  • HY-16445

    CS682; CYC682

    Nucleoside Antimetabolite/Analog Cancer
    Sapacitabine is an orally available nucleoside analog proagent that is structurally related to cytarabine.
    Sapacitabine
  • HY-14792

    Efatutazone; CS-7017; RS5444

    PPAR Cancer
    Inolitazone a novel high-affinity PPARγ agonist that is dependent upon PPARγ for its biological activity with IC50 of 0.8 nM for growth inhibition.
    Inolitazone
  • HY-14792B
    Inolitazone dihydrochloride
    4 Publications Verification

    Efatutazone dihydrochloride; CS-7017 dihydrochloride; RS5444 dihydrochloride

    PPAR Cancer
    Inolitazone dihydrochloride (Efatutazone dihydrochloride) is a novel high-affinity PPARγ agonist that is dependent upon PPARγ for its biological activity with IC50 of 0.8 nM for growth inhibition.
    Inolitazone dihydrochloride
  • HY-14955

    MB06322; CS-917

    FBPase Metabolic Disease
    Managlinat dialanetil (MB06322) is an orally bioavailable inhibitor of fructose 1,6-bisphosphatase (FBPase) for the treatment of type 2 diabetes .
    Managlinat dialanetil
  • HY-N7101

    U-76,252; CS-807

    Bacterial Antibiotic Penicillin-binding protein (PBP) Infection
    Cefpodoxime proxetil is an orally administered broad spectrum third-generation cephalosporin. Cefpodoxime proxetil has anti-bacterial activity. Cefpodoxime proxetil binds to penicillin binding proteins (PBPs) which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis .
    Cefpodoxime Proxetil
  • HY-B0023S

    CS-905-d7

    Calcium Channel Cardiovascular Disease
    Azelnidipine-d7 is deuterium labeled Azelnidipine, which is a L-type calcium channel blocker.
    Azelnidipine-d7
  • HY-50935S

    CS-045-d4

    Isotope-Labeled Compounds PPAR Autophagy Apoptosis Ferroptosis Cancer
    Troglitazone-d4 is deuterium labeled Troglitazone. Troglitazone is a PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively.
    Troglitazone-d4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: